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Abstract
Purpose The aim of this study was to determine an
association between the ADRB1 1165C>G and 145A>G
polymorphisms and hemodynamic response [heart rate
(HR), systolic (SBP) and diastolic (DBP) blood pressure]
to dobutamine during dobutamine stress echocardiography
(DSE).
Methods The study involved 144 patients with clinical
indications for DSE. The PCR–restriction fragment length
polymorphism method was used to identify the ADRB1
1165C>G and 145A>G polymorphisms.
Results Heart rate during DSE increased in all analyzed
study groups. Patients with the ADRB1 1165CC and
1165CG+GG polymorphisms demonstrated similar HR,
including magnitude of response [change in heart rate
(ΔHR 0–30): 42.1±17.5 vs. 46.1±15.5 bpm, respectively].
HR and ΔHR 0–30 were comparable in ADRB1145AA and
145AG subjects in the course of DSE. SBP and DBP at all
stages of DSE were similar in subjects with either
polymorphism and did not differentiate patients with the
ADRB1 145AA polymorphism from those with the ADRB1
145AG polymorphism, nor those with the ADRB1 1165CC
polymorphism from those with the ADRB1 1165CG+GG
polymorphism. No differences were noted in the magnitude
of response, with the increase in SBP and DBP comparable
in all genotypes. Similar observations were made in patients
(25/144 studied) with atropine requirements during DSE.
Conclusion The ADRB1 1165C>G and 145A>G polymor-
phisms are not associated with the HR, SBP and DBP
responses in Polish Caucasian patients requiring diagnostic
dobutamine stress echocardiography
Keywords ADRB1.1165C>G and 145A>G
polymorphisms.Dobutamine stress echocardiography
Introduction
The regulation of cardiovascular response, i.e. heart rate
(HR) and blood pressure [both systolic (SBP) and diastolic
(DBP)], during physical stress is controlled by both
environmental and genetic factors. With respect to the
latter, data are available that demonstrate the association of
several genes, such as those encoding the beta1-adrenergic
receptor [1, 2], G-protein alpha subunit [3, 4] and G-protein
beta3 subunit [5], with effects on the response rate as
measured by HR and BP.
The beta-adrenoreceptor system plays an important role
in the regulation of the human cardiovascular system. Two
common polymorphisms have been identified in the beta1-
adrenergic receptor gene: ADRB1 Arg389Gly (rs1801253,
c.1165C>G in exon 1) and Ser49Gly (rs1801252,
c.145A>G in exon 1). In vitro studies have provided
evidence for their functional basis, and these polymor-
phisms have been implicated in the differential response to
β1-agonists and antagonists in numerous studies [6–10].
However, little information has been published on the
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stress situations, and the results that have been studied are
contradictory, ranging from reports of a significant associ-
ation to a complete lack of influence [12–14].
Dobutamine is an inotropic synthetic catecholamine
commonly used as a diagnostic tool for dobutamine stress
echocardiography (DSE). Due to the positive inotropic and
chronotropic effects of dobutamine, DSE has become a
popular diagnostic tool for the evaluation of coronary artery
disease in patients unable to undergo standard exercise
stress tests. However, based on clinical observations, there
are interpersonal variations in the response to dobutamine
or the exercise test in terms of HR (with some patients
requiring atropine administration due to an inability to
complete the test and achieve target HR) and BP response
[11–13]. Polymorphisms in genes involved in regulating
heart function may shed light on the observed diversity in
heart response to dobutamine. One of the potential
candidates is the ADRB1 gene.
The aim of this study was to determine an association
between ADRB1 gene polymorphisms and hemodynamic
response (namely, HR, SBP and the DBP) to dobutamine
during DSE.
Methods
Subjects
The study cohort consisted of 144 patients of Caucasian
origin (77 women, 67 men; age range 31–80 years) with a
clinical indication for DSE. Of these 144 patients, 25
required atropine administration during DSE. DSE is
standardly indicated for the detection of coronary artery
disease in subjects who are unable to undergo standard
exercise stress testing. A detailed description of the
characteristics of the patients recruited for the study is
presented in Table 1. The study protocol was approved by
the local ethics committee (Pomeranian Medical University,
Szczecin, Poland), and all study participants gave informed
written consent.
Clinical assay
Dobutamine stress echocardiography was performed
according to standard guidelines in which the administra-
tion of dobutamine is steadily increased over time (from 10,
20, 30 to 40 μg/kg/min at 3-min intervals) [15]. The HR
(based on 12-lead electrocardiogram) and BP were mea-
sured at baseline (after a rest period), at the start of the
dobutamine infusion period and at the end of each 3-min
interval. In patients with atropine requirements, i.e. in
subjects who were not able to reach target HR at a
dobutamine dose of 30 μg/kg/min, the drug was adminis-
tered in divided doses, beginning at 0.25 mg and increasing
to 1.0 mg. Most patients evaluated reached target HR at a
dobutamine level of 30 μg/kg/min, which was then taken
for all subjects to be the end time-point for analysis.
Each subject discontinued beta-blockers and/or calcium
channel blockers at least five half-lives of the drug
before study onset.
Genotyping
Genomic DNA was extracted from samples of peripheral
blood leukocytes according to a standard protocol. Geno-
typing of the ADRB1 Arg389Gly (rs1801253, c.1165C>G
in exon 1) and Ser49Gly (rs1801252, c.145A>G in exon 1)
polymorphisms, using a PCR–restriction fragment length
polymorphism (RFLP) method with BsmFI and Eco0109I
restriction enzymes, respectively, was performed as de-
scribed previously [16].
Statistical analysis
Based on allele frequencies, it was expected that the
number of ADRB1 1165GG and 145GG homozygotes
would be low. As such, it was planned a priori that in our
analysis ADRB1 1165GG and 145GG homozygotes would
be combined with ADRB1 1165GG and 145GG hetero-
zygotes. Conformity of genotype distributions to the
Hardy–Weinberg law was assessed using χ
2-test. Categor-
ical baseline characteristics were compared between
Table 1 Patient characteristics
Parameter Patient data
Age (years) 59.3±8.8
Sex
Female 65 (54.62)
Male 54 (45.38)
Body mass index (kg/m
2) 27.8±3.85
Smoking 19 (15.97)
Hypertension 78 (65.55)
Diabetes 15 (12.60)
Medication
Angiotensin-converting enzyme 55 (46.22)
Acetylsalicylic acid 72 (60.50)
Beta-blockers 68 (57.14)
Ca
2+-blockers 23 (19.33)
Statins 68 (57.14)
Diuretics 28 (23.53)
Patient data are given as the mean ± standard deviation (SD) or as the
number of patients (n) with the percentage of patient population given
in parenthesis
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Statsoft Software, Warsaw, Poland). Numerical variables
between groups were evaluated by the Mann–Whitney U
test. A p level <0.05 was considered to be statistically
significant.
Results
The patients were stratified into two groups based on the
identification of the ADRB1 1165C>G or 145A>G poly-
morphism. No significant differences between the groups
were found for the parameters presented in Table 1 (general
patient data), namely, age, sex, body mass index (BMI),
smoking habits, coexistent cardiovascular diseases and
medication. Genotype and allele distributions fit the
Hardy–Weinberg equilibrium in both study groups. Taking
into account the observed genotype frequencies and the
standard deviation (SD), for 119 patients this study has
a >80% power to detect differences in SBP, DBP and HR if
they exceed 9.5, 5.8 and 6.4, respectively, for the Ser49Gly
polymorphism and 8.5, 5.0 and 5.5, respectively, for
theArg389Gly polymorphism. For differences between
starting parameters and those observed after the adminis-
tration of 30 μg of dobutamine, our study has a >80%
power when the difference in the mean values between
genotype-stratified patients would be >11.6 (ΔSPB), 4.9
(ΔDBP) and 10.4 (ΔHR) for the Ser49Gly polymorphism
and 10.0, 4.3 and 9.1, respectively, for the Arg389Gly
polymorphism.
Resting hemodynamics
All resting hemodynamic parameters were similar in
ADRB1 1165C>G and 145A>G carriers. Patients with
ADRB1 1165CC and 1165CG+GG as well as the 145AA
and 145AG genotypes were characterized by comparable
resting HR, SBP and DBP (Table 2).
HR, SBP and DBP response during DSE
The heart rate during DSE increased in all analyzed
groups of the study. Patients with the ADRB1 1165CC or
1165CG+GG polymorphism had similar HR, including
magnitude of response (ΔHR 0–30: 42.1±17.5 vs. 46.1±
15.5 bpm, respectively). Likewise, the HR in the course of
DSE and ΔHR 0–30 were comparable in ADRB1145AA
and 145AG subjects (Table 3).
Table 2 Resting systolic blood pressure, diastolic blood pressure and heart rate
ADRB1 polymorphism Genotype Mean SBP (mmHg) p
a Mean DBP (mmHg) p
a Mean HR (bpm) p
a
145A>G AA (n=90) 133.4±15.7 0.948 83.4±9.8 0.655 70.5±10.7 0.104
AG (n=29) 133.6±16.4 82.8±8.4 66.9±9.8
1165C>G CC (n=67) 132.4±15.2 0.516 83.3±9.3 0.719 69.3±10.1 0.800
GC+GG (n=52) 134.7±16.7 83.3±9.8 70.0±11.2
All values are given as the mean ± SD
SBP, Resting systolic blood pressure, DBP, resting diastolic BP; HR, heart rate
aSignificance was determined using the Mann–Whitney test U test
Table 3 Heart rate and increase in heart rate (ΔHR) at consecutive stages of DSE
Dobutamine dose (μg/kg/min)
a ADRB1 145A>G p
b ADRB1 1165C>G p
b
AA (n=90) AG (n=29) CC (n=67) GC+GG (n=52)
HR 0 70.5±10.7 66.9±9.8 0.104 69.3±10.1 70.0±11.2 0.800
HR 10 75.7±10.6 71.7±9.2 0.079 74.8±10.3 74.7±10.6 0.735
HR 20 92.7±17.3 89.3±10.5 0.347 92.9±19.5 90.5±16.2 0.456
HR 30 112.6±19.9 113.0±18.3 0.988 114.5±19.4 110.5±19.5 0.286
ΔHR 0–30 42.1±17.5 46.1±15.5 0.211 45.1±18.1 40.5±15.4 0.193
All values are given as the mean ± SD
DSE, Dobutamine stress echocardiography
aHR 0, 10, 20, 30, Heart rate at baseline and at 10, 20, 30 μg/kg/min dobutamine, respectively; ΔHR, Change in heart rate from baseline and the end of the
experiment
bSignificance was determined using the Mann–Whitney test U test
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with either polymorphism and did not differentiate ADR-
B1145AA from 145AG subjects, and ADRB1 1165CC from
1165CG+GG cases. Differences were noted in magnitude
of response (Table 4).
DBP response in the course of DSE was similar in both
analyzed polymorphisms of ADRB1 gene. DBP decreased
during DSE at a rate comparable in all analyzed ADRB1
subgroups. A similar trend was observed for magnitude of
DBP response (Table 5).
Similarly to patients not requiring atropine, subjects with
atropine demands were characterized by similar HR, SBP,
DBP and magnitude of hemodynamic response in all
analyzed groups of ADRB1 polymorphisms (except for
some isolated SBP measurements) (Table 6).
Discussion
The aim of this study was to define the role of the ADRB1
1165C>G and 145A>G polymorphisms in interindividual
variability to dobutamine response during DSE (among
patients with clinical indication for the test). The data
currently available are not consistent regarding the associ-
ations of ADRB1 single nucleotide polymorphisms with
hemodynamic response during stress situations, including
DSE. Our results did not demonstrate a significant
association between the ADRB1 1165C>G and 145A>G
polymorphisms and three parameters of hemodynamic
response during DSE, i.e. HR, SBP and DBP, or with the
magnitude of response of these parameters, both in patients
with and without atropine requirements within the con-
straints of the standard DSE protocol. These observations
are in keeping with the data reported by Aquilante et al. [2]
who did not demonstrate any influence of the ADRB1
1165C>G and 145A>G polymorphisms on HR, SBP and
DBP response in American Caucasians during DSE, which
had been clinically indicated (with four drug half-lives of
beta-adrenolytics withdrawal before the study onset).
Similar observations were also reported by Kindermann et
al. [17], who studied the effect of dobutamine administered
in the DSE protocol on HR, SBP and contractility
Table 5 Diastolic blood pressure and its increase (ΔDBP) at consecutive stages of DSE
Dobutamine dose (μg/kg/min)
a ADRB1 145A>G p
b ADRB1 1165C>G p
b
AA (n=90) AG (n=29) CC (n=67) GC+GG (n=52)
DBP 0 83.4±9.8 82.8±8.4 0.655 83.3±9.3 83.3±9.8 0.719
DBP 10 87.6±10.5 83.5±13.7 0.181 87.0±11.6 86.2±11.3 0.900
DBP 20 84.0±9.5 82.7±9.5 0.319 83.3±10.4 84.3±8.1 0.573
DBP 30 80.8±9.0 79.9±11.2 0.719 80.1±10.6 81.3±8.1 0.443
ΔDBP 0-30 −2.6±7.9 −2.9±8.9 0.890 −3.2±7.9 -1.9±8.4 0.664
All values are given as the mean ± SD
aDBP 10, 20, 30, Diastolic blood pressure at baseline and at 10, 20 and 30 μg/kg/min dobutamine, respectively; ΔDBP 0-30, change in Diastolic blood
pressure from baseline to end of experiment
bSignificance was determined using the Mann–Whitney test U test
Table 4 Systolic blood pressureand its increase (ΔSBP) at consecutive stages of DSE
Dobutamine dose (μg/kg/min)
a ADRB1 145A>G p
b ADRB1 1165C>G p
b
AA (n=90) AG (n=29) CC (n=67) GC+GG (n=52)
SBP 0 133.4±15.7 133.6±16.4 0.948 132.4±15.2 134.7±16.7 0.516
SBP 10 138.5±16.0 138.2 ±16.9 0.988 137.7±16.2 139.3±16.3 0.679
SBP 20 146.7±19.4 147.6±21.7 0.861 146.2±20.0 147.8±19.9 0.796
SBP 30 150.5±20.2 150.9±27.2 0.948 149.6±22.2 151.9±21.9 0.530
ΔSBP 0-30 17.1±16.9 17.3±25.1 0.719 17.1±20.6 17.2±17.2 0.755
All values are given as the mean ± SD
aSBP, 10, 20, 30, Systolic blood pressure at baseline and at 10, 20 and 30 μg/kg/min dobutamine, respectively; ΔSBP 0-30, change in systolic blood
pressure from baseline to end of experiment
bSignificance was determined using the Mann–Whitney test U test
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between the ADRB1 1165C>G and 145A>G polymor-
phisms and HR and SBP, although the ADRB1 1165C>G
polymorphism was associated with other hemodynamic
parameters (systemic vascular resistance, ventricular end-
systolic meridional wall stress). The ADRB1 145A>G
polymorphism had no effect on any of the measured
parameters. The findings of our study and those of
Aquilante et al. [2] and Kindermann et al. [17] are in
contrast to data on a German population presented by La
Rosee et al. [14]. These authors evaluated the influence of
the ADRB1 1165C>G polymorphism on hemodynamic
response in healthy volunteers premedicated with atropine
in order to block the parasympathetic system. They found a
significant association between the ADRB1 polymorphism
and SBP, with ADRB1 1165CC homozygotes having a
greater increase in the SBP response to dobutamine during
DSE than carriers of the 1165GG polymorphism. The
differences between our findings and those of Aquilante et
al. [2] and La Rosee et al. [14] may possibly be attributed to
Table 6 Heart rate, SBP, DBP and increase in heart rate (ΔHR), SBP (ΔSBP) and DBP (ΔDBP) at consecutive stages of DSE in patients
requiring atropine administration
Dobutamine dose (μg/kg/min) ADRB1 145A>G p ADRB1 1165C>G p
a
AA (n=17) AG+GG (n=8) CC (n=16) GC+GG (n=9)
HR 0 69.1±11.9 65.3 ±10.0 0.406 68.4±12.1 67.0±10.2 0.760
HR 10 71.5±12.0 72.6 ±12.7 0.887 74.3±12.9 67.7±9.3 0.419
HR 20 76.6±15.4 82.5 ±11.7 0.215 82.7±15.7 71.0±7.7 0.074
HR 30 108.6±23.4 117.3±22.4 0.406 117.1±21.5 101.1±23.1 0.108
ΔHR 0-30 39.5±23.7 52.0 ±23.2 0.215 48.8±23.6 34.1±22.4 0.121
SBP 0 79.1±8.1 79.6±11.5 0.977 122.4±14.0 130.4±17.3 0.276
SBP 10 79.4±8.4 76.4±12.9 0.754 123.7±16.8 135.8±11.8 0.049
SBP 20 76.9±10.6 76.1±13.1 0.842 131.9±15.7 129.6±16.3 1.000
SBP 30 80.6±10.1 81.0±10.2 0.842 142.0±17.7 135.0±15.6 0.388
ΔSBP 0-30 13.4±17.4 15.9±18.7 0.932 19.6±16.5 4.6±15.6 0.043
DBP 0 79.1±8.1 79.6±11.5 0.977 78.1±10.1 81.2±6.9 0.419
DBP 10 79.4±8.4 76.4±12.9 0.754 76.9±10.7 81.1±8.0 0.251
DBP 20 76.9±10.6 76.1±13.1 0.842 76.9±12.0 76.1±10.1 0.677
DBP 30 80.6±10.1 81.0±10.2 0.842 79.5±11.0 82.9±7.6 0.452
ΔDBP 0-30 1.5±8.7 1.4±15.4 0.511 1.4±12.1 1.7±9.0 0.846
All values are given as the mean ± SD
aSignificance was determined using the Mann–Whitney test U test
Table 7 Summary of studies of ABCB1 polymorphism associations with hemodynamic response
ADRB1
polymorphisms
Type of subjects Number of
subjects
Type of
stress
Results Reference
1165C>G
145A>G
Patients with
indications for DSE
163 (132
Caucasians; 26
Blacks; 7 others
DSE No association between the polymorphisms and
HR, SBP, DBP and magnitude of response
[2]
1165C>G Healthy male
volunteers
premedicated with
atropine
30 Caucasians DSE Association between the polymorphism and SBP [14]
1165C>G
145A>G
Patients with
indications for
exercise test
890 Caucasians Exercise
test
Association between ADRB1 1165C>G maximal
SBP during exercise and SBP changes from rest
to maximal
[13]
1165C>G
145A>G
Healthy male
volunteers
38 Caucasians DSE No association between the polymorphisms and
HR, SBP
[17]
1165C>G
145A>G
Patients with
indications for DSE
144 Caucasians DSE No association between the polymorphisms and
HR, SBP, DBP and magnitude of response
Present
study
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that of Aquilante et al. [2] were recruited among patients
with a clinical indication for DSE, while La Rosee et al.
analyzed healthy volunteers [14]. However, the negative
results reported by Kindermann et al. [17] were also from a
healthy population. Another factor which should be
considered is the parasympathetic system blockade intro-
duced by La Rosee et al. [14] with atropine administration;
this might attenuate the genotype-related response to
dobutamine in our patients and those of Aquillante et al.
[2]. La Rosee et al. administered atropine to healthy
volunteers prior to the study and observed effects of the
ADRB1 polymorphism under cholinergic blockade, whereas
the patients from our study requiring atropine to complete
the DSE were not stratified according ADRB1 polymor-
phisms. HR was also not associated with the ADRB1
1165C>G and 145A>G polymorphisms in Finnish study
conducted in patients subjected to an exercise test based on
clinical indication. In this latter study, an association was
noted between ADRB1 1165C>G maximal SBP during
exercise and SBP changes from rest to maximal [13]. A
summary of studies conducted on the association of
hemodynamic changes during stress with the ADRB1
polymorphisms is presented in Table 7.
The parameter which was not affected by the ADRB1
1165C>G polymorphism in the three studies cited above
was HR during DSE. All studies provided evidence that the
ADRB1 polymorphism is not associated with HR response
during DSE.
In summary, the ADRB1 1165C>G and 145A>G poly-
morphisms are not associated with the HR, SBP and DBP
response in Polish Caucasian patients undergoing diagnos-
tic dobutamine stress echocardiography.
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